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SCLEROTHERAPY VERSUS TRANSECTION FOR
ACUTE VARICEAL BLEEDING
ABSTRACT
Burroughs, A.K., Hamilton, G. Phillips, A., Mezzanotte, G., Mclntyre, N. and
Hobbs, K.E.F. (1989) A comparison of sclerotherapy with staple transection of the
esophagus for the emergency control of bleeding from esophagus varices. The New
England Journal of Medicine; 321:857-862
We compared two procedures for the emergency treatment of bleeding esophageal
varices in patients who did not respond to blood transfusion and vasoactive drugs.
We randomly assigned 101 patients with cirrhosis of the liver and bleeding esopha-
geal varices to undergo either emergency sclerotherapy (n 50) or staple transec-
tion of the esophagus (n 51). Four patients assigned to sclerotherapy and 12
assigned to staple transection did not actually undergo those procedures, but all
analyses were made on an intention-to-treat basis.
Total mortality did not differ significantly between the two groups; the relative
risk of death for staple transection as compared with sclerotherapy was 0.88 (95
percent confidence interval, 0.51 to 1.54). Mortality at six weeks was 44 percent
among those assinged to sclerotherapy and 35 percent among those assigned to staple
transection. Complication rates were similar for the two groups. An interval of five
days without bleeding was achieved in 88 percent of those assigned to staple
transection and in 62 percent of those assinged to sclerotherapy after a single
injection (P 0.01) and 82 percent after three injections. In only 2 of the 11 patients
who received a third sclerotherapy injection was bleeding controlled for more than
five days, and 9 died.
We conclude that staple transection of the esophagus is as safe as sclerotherapy for
the emergency treatment of bleeding esophageal varices and that it is more effective
than a single sclerotherapy procedure. We currently recommend surgery after two
injection treatments have failed. (N Engl. J. Med. 1989; 321: 857-62).
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The paper by Burroughs et al., is one of several important contributions which have
originated from this group, concerned with the management of variceal bleeding.
The prospective randomised controlled trial in question, aimed to compare injec-
tion sclerotherapy with stapling oesophageal transaction for the management of
active oesophageal varix bleeding. Clear definitions of eligibility and end-points for
the trial were pre-determined, as were the number of patients to be enrolled. The
ability to control active bleeding was similar for both treatment groups, as was short
and long-term survival. Injection sclerotherapy was associated with a higher
frequency of early and late rebleeding.
The failure to show a significant difference in control of bleeding or survival
between these two treatment groups is in keeping with other studies that have
compared injection sclerotherapy to oesophageal transection or shunt surgery1’2.
This would appear to suggest a large degree of interchangeability between endo-
scopic and surgical techniques for managing active bleeding. However, some
concern must be expressed as to whether injection sclerotherapy was used opti-
mally. Entry criteria into the trial in question was restricted to patients who
continued to bleed over a period up to 5 days after first presentation with evidence
of variceal haemorrhage. All patients underwent an initial endoscopic assessment,
but this itself did not determine the type or timing of treatment. The patients were
then followed and assessed for active bleeding, but were not randomised unless
there was evidence of haemodynamically significant bleeding or a minimum of 6
units of blood transfused within a 24-hour period. For bleeding of any less severity
the patients were volume repleted and received vaso-active drugs at the discretion
of the attending physicians. The fact that many of the patients included in the study
had experienced further major bleeding after initial presentation is substantiated by
the median blood transfusion before randomisation which was 13 units, ranging
between 5 and 34 units of blood. By the time of inclusion in the study, the majority
of the patients had received some form of vasoactive drug and/or balloon tampo-
nade. Whether such delayed intervention with injection sclerotherapy might have
reduced the efficacy remains speculation, although there is evidence that imme-
diate injection sclerotherapy at the time of the diagnostic endoscopy has a success
rate of approximately 85-90% 3,4 higher than observed in the present study. There
is also some evidence that prior treatment with vasoactive drugs might also reduce
the efficacy of injection sclerotherapy, perhaps by exacerbating mucosal damage5.
The possibility that delayed intervention might also influence the outcome from
oesophageal transection could equally be proposed.
The authors justify delaying intervention on the basis that many patients would
be treated unnecessarily as spontaneous cessation of bleeding is not uncommon.
However, in the present study, some 60% of patients either continued to bleed or
had early rebleeding (justifying randomisation into the study). Early intervention
to arrest active bleeding and to prevent early rebleeding would be justified in all
cases if such treatment was both safe and effective. Cost implications must also be
considered. It may be argued that the diagnostic endoscopy offers the optimum
time for early intervention utilising a technique that is relatively safe, effective andHPB INTERNATIONAL 329
cheap. Whether initial treatment should be extended to long-term regimes is a
point of contention beyond the scope of the present article.
An extremely important point emphasised by the authors is the definition of
treatment failure, particularly with reference to injection sclerotherapy. They have
clearly shown that repeated attempts to manage bleeding by sclerotherapy are
associated with diminishing returns and it is suggested that 2 attempts at endoscopic
treatment is all that is justified before recourse to other measures. The results of
stapling transection observed in the present trial would strongly support this
technique for the early rescue of patients who have failed endoscopic therapy. Any
such intervention should be considered over a period of hours rather than days
after the time of presentation. The only reservation with respect to this advice may
be the possible adverse effect of staple transection upon any subsequently planned
liver transplantation.
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